Masanori Atsukawa

Dr. Masanori Atsukawa


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KTKazunari Tanaka
Kazunari Tanaka
KTKunihiko Tsuji
Kunihiko Tsuji
AHAtsushi Hiraoka
Atsushi Hiraoka
TTToshifumi Tada
Toshifumi Tada
MHMasashi Hirooka
Masashi Hirooka
HTHidenori Toyoda
Hidenori Toyoda
Aim: This study aimed to evaluate the ability of a previously reported tumor marker (TM) score involving alpha-fetoprotein (AFP), fucosylated AFP (AFP-L3), and des gamma-carboxy prothrombin (DCP) as TMs in predicting the prognosis and therapeutic efficacy in hepatocellular carcinoma (HCC) patients administered atezolizumab plus bevacizumab (Atez/Bev) as first-line treatment. Materials/Methods: The study period covered September 2020 to December 2022 and involved 371 HCC patients treated with Atez/Bev. The values of the TMs AFP, AFP-L3, and DCP were measured upon introducing Atez/Bev. Elevations in the values of AFP (≥100 ng/mL), AFP-L3 (≥10%), and DCP (≥100 mAU/mL) were considered to indicate a positive TM. The number of positive TMs was summed up and used as the TM score, as previously proposed. Hepatic reserve function was assessed using the modified albumin–bilirubin grade (mALBI). Predictive values for prognosis were evaluated retrospectively. Results: A TM score of 0 was shown in 81 HCC patients (21.8%), 1 in 110 (29.6%), 2 in 112 (29.9%), and 3 in 68 (18.3%). The median overall survival (OS) times for TM scores 0, 1, 2, and 3 were not applicable [NA] (95% CI NA-NA), 24.0 months (95% CI 17.8-NA), 16.7 months (95% CI 17.8-NA), and NA (95% CI 8.3-NA), respectively (p < 0.001). The median progression-free survival (PFS) times for TM scores 0, 1, 2, and 3 were 16.5 months (95% CI 8.0-not applicable [NA]), 13.8 months (95% CI 10.6–21.3), 7.7 months (95% CI 5.3–8.9), and 5.8 months (95% CI 3.0–7.6), respectively (p < 0.001). OS was well stratified in mALBI 1/2a and mALBI 2a/2b. PFS was well stratified in mALBI 2a/2b, but not in mALBI 1/2a. Conclusions: The TM score involving AFP, AFP-L3, and DCP as TMs was useful in predicting the prognosis and therapeutic efficacy in terms of OS and PFS in HCC patients administered Atez/Bev as first-line treatment.

1 January 2021 in Journal of Nippon Medical School
Verified
Journal Article
Closed access
PDF file
MAMasanori Atsukawa
Masanori Atsukawa
CKChisa Kondo
Chisa Kondo
TKTadamichi Kawano
Tadamichi Kawano
TOTomomi Okubo
Tomomi Okubo
TATaeang Arai
Taeang Arai
KIKatsuhiko Iwakiri
Katsuhiko Iwakiri
Chronic hepatitis C virus (HCV) infection can progress to liver cirrhosis and hepatocellular carcinoma. Interferon-based treatment was previously the only antiviral therapy for chronic hepatitis C infection; however, development of interferon-free, direct-acting antivirals, in 2014, markedly improved treatment efficacy and safety. Treatment indications were expanded to include elderly adults, patients with advanced liver fibrosis, and patients with chronic hepatitis C infection complicated by chronic kidney disease, for whom antiviral therapy had been difficult or contraindicated. The median age of patients with chronic HCV infection in Japan is 70 years, older than in other countries. Because diminished renal function is common in elderly adults, a safe and effective treatment for chronic hepatitis C complicated by chronic kidney disease has been expected in Japan. In addition, the HCV antibody-positive rate is higher in hemodialysis patients than in non-hemodialysis patients in Japan. Numerous studies have reported that direct-acting antivirals are safe and effective for hepatitis C patients on hemodialysis. This review summarizes treatments available in Japanese clinical practice for patients with chronic HCV infection complicated by chronic kidney disease, including hemodialysis patients.

10 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
TNTakayoshi Nishimoto
Takayoshi Nishimoto
ATAtsushi Tatsuguchi
Atsushi Tatsuguchi
TYTakeshi Yamada
Takeshi Yamada
SKSho Kuriyama
Sho Kuriyama
AHAitoshi Hoshimoto
Aitoshi Hoshimoto
MAMasanori Atsukawa
Masanori Atsukawa
Background/Objectives: The Wnt signaling pathway is pivotal in the adenoma–carcinoma sequence; however, its role in small bowel adenocarcinoma (SBA) remains insufficiently characterized. We analyzed the clinicopathological significance of Wnt pathway-related gene mutations and the expression of downstream or associated proteins in SBA. Methods: Immunohistochemical staining for β-catenin, cyclin D1, c-Myc, E-cadherin, and Wnt5a was performed in 75 primary SBA surgical specimens. Targeted next-generation sequencing was conducted in 48 of these cases. Results: The genomic alterations in the Wnt pathway were identified as APC (14.6%) and CTNNB1 (8.3%), with no overlap between the two mutations. Aberrant (reduced membranous and/or nuclear) expression of β-catenin was observed in 37% of cases. Cyclin D1 and c-Myc were expressed in 60% and 41% of cases, respectively. Aberrant expression of β-catenin and/or Wnt5a was present in 60% of cases and was correlated with cyclin D1 and c-Myc expression. Mutations in APC and CTNNB1 were found in intestinal- and gastrointestinal-type SBAs, but were absent in gastric-type SBA. In intestinal-type SBA, the mutation frequency of APC and CTNNB1 was 39%, closely aligning with the 45% aberrant expression of β-catenin. Aberrant expression of β-catenin and/or Wnt5a, a ligand of the noncanonical Wnt pathway, was detected in 60% of cases and showed a correlation with both cyclin D1 and c-Myc expression. Conclusions: These findings suggest that both canonical and noncanonical Wnt pathway-related proteins are involved in SBA carcinogenesis and progression. Notably, the canonical Wnt pathway appears to play a predominant role in intestinal-type SBA.

4 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
NANaohiko Akimoto
Naohiko Akimoto
SNShun Nakagome
Shun Nakagome
RIRyosuke Inoue
Ryosuke Inoue
RMRina Motomiya
Rina Motomiya
YSYuka Shimazu
Yuka Shimazu
MAMasanori Atsukawa
Masanori Atsukawa
Background: The incidence of colorectal cancer diagnosed before age 50 has been increasing worldwide. However, limited data describe the endoscopic and pathological features of colorectal lesions encountered and treated during routine colonoscopy in younger adults. This study aimed to characterize age-related differences in endoscopically resected colorectal neoplasia. Methods: We conducted a retrospective, single-center observational study of consecutively endoscopically resected colorectal neoplasia at a high-volume academic teaching hospital in Japan. Patient-level and lesion-level characteristics were compared between early-onset (<50 years) and later-onset (≥50 years) groups. Lesions were evaluated for location, morphology, size, histology, resection method, and advanced neoplasia status. Results: A total of 1299 patients with 3399 lesions were analyzed, including 498 early-onset patients with 940 lesions. Early-onset neoplasia showed a left-sided predominance, with higher proportions in the distal colon and rectum. Pedunculated morphology was more frequently observed in early-onset lesions. Early-onset disease was also associated with larger lesion size, a higher prevalence of high-grade tubular adenoma, and increased rates of advanced adenoma and advanced neoplasia, resulting in more frequent use of endoscopic mucosal resection or submucosal dissection. Conclusions: Endoscopically resected colorectal lesions in younger adults exhibit distinct anatomical and morphological features compared with later-onset cases, indicating heterogeneity at the premalignant stage.

6 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TNTakayoshi Nishimoto
Takayoshi Nishimoto
ATAtsushi Tatsuguchi
Atsushi Tatsuguchi
TYTakeshi Yamada
Takeshi Yamada
SKSho Kuriyama
Sho Kuriyama
AHAitoshi Hoshimoto
Aitoshi Hoshimoto
MAMasanori Atsukawa
Masanori Atsukawa
Background/Objectives: The Wnt signaling pathway is pivotal in the adenoma-carcinoma sequence; however, its role in small bowel adenocarcinoma (SBA) remains insufficiently characterized. We analyzed the clinicopathological significance of Wnt pathway-related gene mutations and the expression of downstream or associated proteins in SBA. Methods: Immunohistochemical staining for β-catenin, cyclin D1, c-Myc, E-cadherin, and Wnt5a was performed in 75 primary SBA surgical specimens. Targeted next-generation sequencing was conducted in 48 of these cases. Results: Genomic alterations in the Wnt pathway were identified as APC (14.6%) and CTNNB1 (8.3%), with no overlap between the two mutations. Aberrant (reduced membranous and/or nuclear) expression of β-catenin was observed in 37% of cases. Cyclin D1 and c-Myc were expressed in 60% and 41% of cases, respectively. Aberrant expression of β-catenin and/or Wnt5a was present in 60% of cases and correlated with cyclin D1 and c-Myc expression. Mutations in APC and CTNNB1 were found in intestinal and gastrointestinal-type SBAs but were absent in gastric-type SBA. In intestinal-type SBA, the mutation frequency of APC and CTNNB1 was 39%, closely aligning with the 45% aberrant expression of β-catenin. Aberrant expression of β-catenin and/or Wnt5a, a ligand of the noncanonical Wnt pathway, was detected in 60% of cases and showed correlation with both cyclin D1 and c-Myc expression. Conclusions: These findings suggest that both canonical and noncanonical Wnt pathway-related proteins are involved in SBA carcinogenesis and progression. Notably, the canonical Wnt pathway appears to play a predominant role in the intestinal-type SBA.